Eliquis 2.5 Mg

Eliquis 2.5 Mg

Description:

Eliquis 2.5 mg is a prescription oral anticoagulant (blood thinner) containing apixaban, a direct factor Xa inhibitor. It is used to prevent and treat serious blood clots and to reduce the risk of stroke and systemic embolism in patients with certain heart rhythm disorders. Eliquis 2.5 mg film-coated tablets are indicated for adults and are part of long-term cardiovascular and thrombosis management under medical supervision.

Indications:

• Reduction of the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) who have one or more risk factors (such as prior stroke or transient ischemic attack, age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure).
• Prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone elective hip or knee replacement surgery.
• Treatment of deep vein thrombosis (DVT) in adults.
• Treatment of pulmonary embolism (PE) in adults.
• Reduction in the risk of recurrent DVT and PE following initial therapy in adults.

Active Ingredients / Key Components:

• Apixaban – 2.5 mg per film-coated tablet.
• Excipients: The full list of inactive ingredients (excipients, colorants, stabilizers) is not available in the provided data. Please refer to the official package leaflet for complete excipient information.

Dosage & Administration / How to Use:

• Eliquis 2.5 mg is for oral use only and should be swallowed with water. It can be taken with or without food.
• Typical dosing for stroke prevention in nonvalvular atrial fibrillation: The usual recommended dose is 5 mg twice daily; however, a reduced dose of 2.5 mg twice daily may be used in patients who meet specific clinical criteria (such as advanced age, low body weight, or impaired kidney function) as determined by their physician. The exact dose and regimen must be prescribed by a healthcare professional.
• Typical dosing for DVT/PE prophylaxis after hip or knee replacement surgery: Often 2.5 mg twice daily, starting 12–24 hours after surgery, for a duration determined by the surgeon (commonly up to 35 days for hip replacement and up to 12 days for knee replacement). Exact duration must follow the doctor’s instructions.
• Typical dosing for treatment of DVT and PE and reduction of recurrence: Usually higher doses are used initially, then may be adjusted; your physician will decide if and when the 2.5 mg strength is appropriate for long-term prevention.
• If a dose is missed: Take it as soon as you remember on the same day and then continue with your regular schedule. Do not take a double dose to make up for a missed dose.
• Do not stop taking Eliquis suddenly without consulting your doctor, as this may increase the risk of stroke, DVT, or PE.
• Always follow the dosing regimen, duration, and monitoring plan prescribed by your healthcare provider. Do not adjust the dose on your own.

Clinical Benefits:

• Helps prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation by reducing the formation of harmful blood clots.
• Reduces the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) after major orthopedic surgery such as hip or knee replacement.
• Provides effective treatment for existing DVT and PE, helping to prevent clot extension and further complications.
• Lowers the risk of recurrent DVT and PE after initial therapy, supporting long-term vascular health and clot prevention.

Warnings & Contraindications:

• Contraindicated in patients with active clinically significant bleeding.
• Contraindicated in patients with severe hypersensitivity to apixaban or any component of the formulation.
• Use with extreme caution in patients with conditions that increase the risk of bleeding, such as recent surgery, history of bleeding disorders, gastrointestinal ulcers, recent brain or spinal injury, or uncontrolled hypertension.
• Not recommended in patients with severe hepatic impairment or hepatic disease associated with coagulopathy and clinically relevant bleeding risk.
• Use with caution in patients with renal impairment; dose adjustment may be required. Your doctor will determine if Eliquis 2.5 mg is suitable for you.
• Concomitant use with other anticoagulants, antiplatelet agents, nonsteroidal anti-inflammatory drugs (nsaids), selective serotonin reuptake inhibitors (ssris), or serotonin–norepinephrine reuptake inhibitors (snris) may increase bleeding risk. Inform your doctor about all medicines and supplements you are taking.
• Spinal/epidural anesthesia or puncture: Patients receiving neuraxial anesthesia or undergoing spinal puncture while on apixaban are at risk of developing an epidural or spinal hematoma, which can result in long-term or permanent paralysis. Careful monitoring and timing of doses are required.
• Consult your doctor before use if pregnant, planning pregnancy, or nursing. The safety of apixaban in pregnancy and breastfeeding is not fully established; it should be used only if the potential benefit justifies the potential risk.
• Consult your doctor before use if you have liver disease, kidney disease, bleeding disorders, recent surgery, history of stroke, or are taking any other medications that affect blood clotting.
• Do not stop or change the dose without medical advice, as abrupt discontinuation may increase the risk of thrombotic events (such as stroke or clot recurrence).
• Keep out of reach of children.
• Not intended to diagnose, treat, cure, or prevent any disease without proper medical supervision. Use only under the guidance of a licensed healthcare professional.

Side Effects:

• Common side effects: Increased risk of bleeding such as nosebleeds, easy bruising, gum bleeding, heavier or prolonged menstrual bleeding, or minor cuts that take longer to stop bleeding.
• Other possible side effects: Anemia (low red blood cell count), nausea, minor gastrointestinal discomfort, or mild skin rash.
• Serious side effects (seek immediate medical attention): Signs of severe bleeding such as coughing or vomiting blood, blood in urine or stools (red or black/tarry stools), severe or unexplained bruising, prolonged bleeding from wounds, severe headache, dizziness, weakness, fainting, vision changes, or any signs of stroke (sudden numbness or weakness, especially on one side of the body; difficulty speaking; confusion; trouble seeing; loss of balance).
• If you experience any unusual symptoms or suspect an adverse reaction, contact your doctor or seek emergency medical care immediately.

Storage Instructions:

Store in a cool, dry place away from direct sunlight and moisture. Keep the blister pack or bottle tightly closed. Do not use after the expiry date printed on the packaging. Keep out of reach of children.

Specifications:

• Strength: 2.5 mg apixaban per film-coated tablet.
• Form: Film-coated tablets for oral administration.
• Pack size: The exact number of tablets per pack (for example, 20 f.c. tabs) is not fully confirmed from the provided data; refer to the product packaging for precise count.
• Intended use: Prescription anticoagulant medicine for adults, used under medical supervision.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.